Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.73 |
| ▸ | NR2E3 | Q9Y5X4 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806384 | 0.87 | MAPT (0.62) | SCDNR2E3PKMMAPTCYP2C9 | |
| SCHEMBL2805121 | 0.85 | SCD (0.71) | SCDKDRMAPTCYP2C9CYP2C19 | |
| SCHEMBL2809774 | 0.80 | KDR (0.57) | SCDKDRMAPTCYP2C9CYP2C19 | |
| SCHEMBL2804172 | 0.78 | SCD (0.69) | SCDNR2E3KDRMAPTCYP2C9 | |
| SCHEMBL2808385 | 0.77 | SCD (0.67) | SCDNR2E3PKMMAPTCYP2C9 | |
| SCHEMBL2804169 | 0.76 | SCD (0.62) | SCDCHEK2 | |
| SCHEMBL2319097 | 0.70 | SCD (0.54) | SCDMAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2319195 | 0.70 | SCD (0.61) | SCDCHEK2 | |
| SCHEMBL2804505 | 0.69 | CHEK2 (0.55) | SCDCHEK2 | |
| SCHEMBL2316895 | 0.69 | SCD (0.56) | SCDCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | claimed |
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | SCD 3183/4885NR2E3 981/4885KDR 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.